Week of November 26, 2012: Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of November 26, 2012: Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical has established a new organization (Global Medical Affairs Japan Department) in Takeda Development Center Japan, Pharmaceutical Development Division, with appointment of its senior leadership, effective Dec. 1, 2012. Along with this, the company’s Strategic Medical Research Planning Division, currently under Takeda Development Center Japan, will be positioned under Global Medical Affairs Japan Department. Koki Nakamura has been named general manager of the new department. Read More

The biopharmaceutical company UCB has announced that Exemed Pharmaceuticals, a manufacturer of APIs, will acquire UCB’s production facility in Vapi, India. The deal includes a multiyear supply agreement between UCB and Exemed as well as the transfer of UCB Vapi’s staff of approximately 80 members to Exemed. Read More

In a separate deal, UCB and NewBridge Pharmaceuticals, a specialty therapeutics company have agreed to make UCB’s core products Cimzia (PEGylated anti-tumor necrosis factor), Vimpat (lacosamide), and Neupro (rotigotine), available in several Middle East and African countries. Under the agreement, NewBridge acquires the rights to Cimzia, Vimpat, and Neupro from the RX Group, UCB’s previous partner in the region. UCB will operate with its new partner for the region and will supply NewBridge with the three products on an exclusive basis. NewBridge will also be responsible for managing the local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here